Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical review of alendronate (Fosamax) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including atypical femoral fractures, osteonecrosis of the jaw, and esophageal events.
Read clinical reviewA complete regulatory guide to alendronate (Fosamax) compounding legal status, FDA approval history, label requirements, and post-market safety data. Reviewed by the HealthRX medical team.
Read clinical reviewA complete, clinically accurate account of Fosamax (alendronate) FDA approval history, label changes, post-market safety updates, and what prescribers and patients need to know in 2025.
Read clinical reviewA complete guide to Fosamax (alendronate) regulatory history across the FDA, EMA, and major markets, including label changes, black-box warnings, and post-market safety findings.
Read clinical reviewA complete review of every FDA label update to Fosamax (alendronate) from 2020 through 2026, including new safety signals, dosing guidance, and post-market surveillance data reviewed by the HealthRX.com medical team.
Read clinical reviewA clinical review of alendronate (Fosamax) regulatory history, patent disputes, FDA label revisions, and major litigation outcomes including the landmark preemption case.
Read clinical review